Universitätsklinikum Würzburg

Running trials

• Not yet recruiting

  A Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies

  NCT07789015· Phase 3· Boehringer Ingelheim· Source

• Not yet recruiting

  A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma

  NCT07728188· Phase 3· AbbVie· Source

• Recruiting

  Mi2000 TICI - Post-market Implantation Study

  NCT07897318· MED-EL Elektromedizinische Geräte GmbH· Source

• Recruiting

  Mi2000 TICI Follow-up

  NCT07902414· MED-EL Elektromedizinische Geräte GmbH· Source

• Recruiting

  A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned

  NCT07665450· Phase 3· Janssen Research & Development, LLC· Source

• Not yet recruiting

  Master Study Protocol for the Cohort of the Specialist Network Stroke (SN Stroke)(Stroke-CORE)

  NCT07553650· Charite University, Berlin, Germany· Source

• Recruiting

  A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

  NCT07492680· Phase 2· Bristol-Myers Squibb· Source

• Recruiting

  Gustabor Phase 2 - Treating Taste Changes During Cancer Therapy: A Randomized Study Evaluating an AI- Based Nutrition Intervention

  NCT07649681· Wuerzburg University Hospital· Source

• Recruiting

  BIO|MASTER.CorSky Family Post-market Study for the CorSky Family of ICDs

  NCT07360158· Biotronik SE & Co. KG· Source

• Recruiting

  A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer

  NCT07365995· Phase 3· BioNTech SE· Source

• Recruiting

  Social Prescriptions and Micro-Learning to Improve Care for Cancer Patients and Their Support Persons

  NCT07788729· University of Regensburg· Source

• Recruiting

  Exploratory Investigation of the Acceptance and Utility of 14-day Trial Periods and Application-related Outcome Measurement (AbEM) Within the Routine Prescription of the DiGA Axia.

  NCT07561255· Wuerzburg University Hospital· Source

• Not yet recruiting

  Multicentric Approval Study Trans-Duodenal Barrier for Typ 2 Diabetes With Obesity

  NCT07417683· Trans-Duodenal Concepts GmbH· Source

• Recruiting

  ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis

  NCT07294170· argenx· Source

• Recruiting

  Study of Cabozantinib in Participants With Neuroendocrine Tumors Who Have Already Received Prior Treatment

  NCT07314164· Ipsen· Source

• Recruiting

  A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

  NCT07218380· Phase 3· Eli Lilly and Company· Source

• Recruiting

  Long-Term Clinical Results of Ab-Interno Trabeculotomy in Glaucoma Management

  NCT07780916· Wuerzburg University Hospital· Source

• Recruiting

  A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

  NCT07213674· Phase 3· Amgen· Source

• Recruiting

  Gustabor Phase 1 - AI-based Creation of a Nutritional Plan to Compensate for Chemotherapy-induced Taste Disorders

  NCT07040189· Wuerzburg University Hospital· Source

• Recruiting

  A Study of Maribavir in Adults With Kidney Failure Who Have a Cytomegalovirus (CMV) Infection After Transplantation

  NCT06243731· Takeda· Source

• Active, not recruiting

  A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)

  NCT07005128· Phase 3· Amgen· Source

• Recruiting

  Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC

  NCT07098988· Phase 2· CatalYm GmbH· Source

• Recruiting

  Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

  NCT06943755· Phase 2/3· Exelixis· Source

• Recruiting

  A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

  NCT06852222· Phase 3· Janssen Research & Development, LLC· Source

• Not yet recruiting

  Pre-Operative Treatment in REseCTable COlon CanceR

  NCT06899477· Phase 3· Dominik Paul Modest· Source

• Recruiting

  LEOPARD Training and Validation Data Collection Study

  NCT06675604· Assistance Publique - Hôpitaux de Paris· Source

• Recruiting

  Peripheral Neuropathy in Patients Receiving Enfortumab Vedotin and Pembrolizumab as First Line Treatment for Metastatic or Locally Advanced Urothelial Carcinoma

  NCT06657157· Comprehensive Cancer Center Munich (CCCM)· Source

• Recruiting

  A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa

  NCT06298565· argenx· Source

• Recruiting

  ColoReg: A Register for Gastrointestinal Endoscopy Reports and Examination Videos

  NCT06920680· Wuerzburg University Hospital· Source

• Active, not recruiting

  Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).

  NCT06333951· Phase 1· Amgen· Source

• Recruiting

  Bilateral Subthalamic Stimulation in PD Patients With Impulse Control Disorders - STIMPulseControl

  NCT06498349· University of Kiel· Source

• Recruiting

  STIMPulseControl Ancillary Speech Study

  NCT06561919· Steffen Paschen· Source

• Recruiting

  Liquid Biopsy Under PSMA Radioligand Therapy

  NCT07118436· Wuerzburg University Hospital· Source

• Active, not recruiting

  A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)

  NCT06285643· Phase 2· AskBio Inc· Source

• Active, not recruiting

  A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)

  NCT06360354· Phase 1· Amgen· Source

• Recruiting

  Corheart 6 LVAS Study

  NCT05876000· Shenzhen Core Medical Technology CO.,LTD.· Source

• Active, not recruiting

  A Research Study to Look at Long-term Treatment With a Medicine Called NNC6019-0001 for People Who Have Heart Failure Due to Transthyretin Amyloidosis

  NCT06260709· Phase 2· Novo Nordisk A/S· Source

• Recruiting

  Radiofrequency (RF) Ablation Prospective Outcomes Study for Central Nervous System - RAPID for CNS

  NCT06553625· Boston Scientific Corporation· Source

• Recruiting

  PROCARE - PROstate Cancer Real World Evidence Registry

  NCT06835218· UroTrials Company (GmbH)· Source

• Recruiting

  A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma

  NCT06091254· Phase 3· Regeneron Pharmaceuticals· Source

• Active, not recruiting

  German Observational Multicenter Study of Patients With Fabry Disease Under Enzyme Replacement Therapy With Pegunigalsidase-alfa

  NCT06095713· Universität Münster· Source

• Active, not recruiting

  Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies

  NCT05753501· Phase 1· AbbVie· Source

• Recruiting

  Sequential or Up-front Triple Treatment With Durvalumab, Tremelimumab and Bevacizumab for Non-resectable Hepatocellular Carcinoma (HCC) Patients

  NCT05844046· Phase 2· Enrico De Toni· Source

• Recruiting

  The DefiPace Study

  NCT04804748· Institut für Pharmakologie und Präventive Medizin· Source

• Recruiting

  Non-interventional Study of Seroprevalence of Pre-existing Antibodies Against Adenovirus-associated Virus Vector (AAV9) and the Progression of Disease in Patients With Plakophilin 2 (PKP2)-Associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)

  NCT06311708· Tenaya Therapeutics· Source

• Recruiting

  Response Prediction of Hyperthermic Intraperitoneal Chemotherapy in Gastro- Intestinal Cancer

  NCT05652348· Technische Universität Dresden· Source

• Enrolling by invitation

  An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

  NCT05667493· Phase 3· Ionis Pharmaceuticals, Inc.· Source

• Active, not recruiting

  RESPONDER-HF Trial

  NCT05425459· Corvia Medical· Source

• Recruiting

  Non-invasive Detection of Iron Deficiency in Obstetrics

  NCT07083492· Wuerzburg University Hospital· Source

• Active, not recruiting

  A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma

  NCT05535244· Phase 1/2· Hoffmann-La Roche· Source

Showing 50 of 92.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Colorectal cancer6 recruiting
• Melanoma5 recruiting
• Parkinson disease5 recruiting
• Dystonia4 recruiting
• Heart failure4 recruiting
• Lung cancer4 recruiting
• Multiple myeloma4 recruiting
• Prostate cancer4 recruiting
• Bladder cancer3 recruiting
• Essential tremor3 recruiting
• Pancreatic cancer3 recruiting
• Acute myeloid leukaemia2 recruiting
• Childhood cancers2 recruiting
• Chronic kidney disease2 recruiting
• Gastric and oesophageal cancer2 recruiting
• Hearing loss2 recruiting
• Metastatic breast cancer2 recruiting
• Myasthenia gravis2 recruiting
• Neuroendocrine tumours2 recruiting
• Ovarian cancer2 recruiting
• Stroke2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• Amyloidosis1 recruiting
• Ankylosing spondylitis1 recruiting
• Atrial fibrillation1 recruiting
• Cervical cancer1 recruiting
• Coronary artery disease1 recruiting
• Cytomegalovirus infection1 recruiting
• Dermatomyositis and polymyositis (myositis)1 recruiting
• Fabry disease1 recruiting
• Follicular lymphoma1 recruiting
• Glaucoma1 recruiting
• Head and neck cancer1 recruiting
• Huntington's disease1 recruiting
• Hypertrophic cardiomyopathy1 recruiting
• Immune thrombocytopenia (ITP)1 recruiting
• Kidney cancer1 recruiting
• Liver cirrhosis1 recruiting
• Obesity1 recruiting
• Polycystic kidney disease1 recruiting
• Primary biliary cholangitis1 recruiting
• Restless legs syndrome1 recruiting
• Sarcoma1 recruiting
• Triple-negative breast cancer1 recruiting
• Type 2 diabetes1 recruiting

Closed trials

• Recruiting

  Safety and Effectiveness of the Orsiro Mission 48-mm Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions

  NCT06779630· Teleflex· Source

• Completed

  A Study of Maribavir in Adults With Post-transplant Cytomegalovirus (CMV) Infection

  NCT06615921· Takeda· Source

• Completed

  Remote Support for Cochlear Implant Recipients: Evaluation of the HearCare MED-EL App

  NCT06543953· MED-EL Elektromedizinische Geräte GmbH· Source

• Completed

  As Part of a Pilot Study, Visualization of Inflammatory Activity in Systemic Sclerosis Using CXCR4 PET/CT

  NCT07212959· Wuerzburg University Hospital· Source

• Terminated

  Radioimmunotherapy With Lu-177 Labeled 6A10 Fab-fragments in Patients With Glioblastoma After Standard Treatment

  NCT05533242· Phase 1· University Hospital Muenster· Source

• Completed

  Levels of Inflammation in People With Cardiovascular Disease (POSEIDON)

  NCT06122961· Novo Nordisk A/S· Source

• Terminated

  A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma

  NCT05529316· Phase 2· Agenus Inc.· Source

• Completed

  Post Market Clinical Follow-up Study for the Pamira ICD Lead Family

  NCT05621187· Biotronik SE & Co. KG· Source

• Completed

  Prednisolone and Vitamin B1/6/12 in Patients With Post-Covid-Syndrome

  NCT05638633· Phase 3· Wuerzburg University Hospital· Source

• Completed

  A Research Study to Look at How a New Medicine Called NNC6019-0001 Works and How Safe it is for People Who Have Heart Disease Due to Transthyretin (TTR) Amyloidosis

  NCT05442047· Phase 2· Novo Nordisk A/S· Source

• Completed

  New Prospective Expanded German Registry of Incidental Gallbladder Carcinoma (PERSUASION)- a Permanent Platform Including All Kind of Biliary Tract Cancers (BTC)

  NCT04896931· Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest· Source

• Completed

  SeMaglutide and Albuminuria Reduction Trial in Obese Individuals Without Diabetes

  NCT04889183· Phase 3· University Medical Center Groningen· Source

• Completed

  Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM

  NCT05186818· Phase 3· Cytokinetics· Source

• Terminated

  A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL)

  NCT04809467· Phase 1/2· Incyte Corporation· Source

• Completed

  A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF)

  NCT05033080· Phase 3· Vertex Pharmaceuticals Incorporated· Source

• Completed

  Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH)

  NCT05016882· Phase 2· Novo Nordisk A/S· Source

• Recruiting

  Special Care Patterns for Elderly HNSCC Patients Undergoing Radiotherapy

  NCT05337631· University Hospital Freiburg· Source

• Terminated

  An Open-Label Phase 2 Trial of Nanatinostat Plus Valganciclovir in Patients With EBV+ Relapsed/Refractory Lymphomas

  NCT05011058· Phase 2· Viracta Therapeutics, Inc.· Source

• Completed

  Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3)

  NCT04880434· Phase 2· Kite, A Gilead Company· Source

• Terminated

  Dose-escalating Trial With UniCAR02-T Cells and PSMA Target Module (TMpPSMA) in Patients With Progressive Disease After Standard Systemic Therapy in Cancers With Positive PSMA Marker

  NCT04633148· Phase 1· AvenCell Europe GmbH· Source

• Completed

  Cartesia eXTend 3D Study

  NCT04577651· Boston Scientific Corporation· Source

• Completed

  Quality Improvement Project - "My Logbook! - I Know my Way Around!"; ("Mein Logbuch - Ich Kenne Mich Aus!")

  NCT04474678· Medical University of Vienna· Source

• Completed

  COVID-19 Infection and Multiple Myeloma

  NCT04492371· Stichting European Myeloma Network· Source

• Completed

  Safety and Tolerance of Epigenetic and Immunomodulating Drugs Combined With Chemotherapeutics in Patients Suffering From Advanced Pancreatic Cancer

  NCT04257448· Phase 1/2· GWT-TUD GmbH· Source

• Completed

  CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)

  NCT04136171· Phase 3· Ionis Pharmaceuticals, Inc.· Source

• Completed

  Can Subthalamic Stimulation Using Directional Electrodes Improve Postoperative Management in Parkinson's Disease

  NCT04578678· Insel Gruppe AG, University Hospital Bern· Source

• Completed

  Dose-Ranging Study of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy in Subjects With Fabry Disease (STAAR)

  NCT04046224· Phase 1/2· Sangamo Therapeutics· Source

• Completed

  PREvention of STroke in Intracerebral haemorrhaGE Survivors With Atrial Fibrillation

  NCT03996772· Phase 3· Imperial College London· Source

• Completed

  Rostock International Parkinson's Disease Study (ROPAD)

  NCT03866603· CENTOGENE GmbH Rostock· Source

• Completed

  Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)

  NCT03867084· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  A Study to Evaluate the Relationship of Lenalidomide With Tumor Flare Reaction and High Tumor Burden in Participants With Relapsed or Refractory Mantle Cell Lymphoma

  NCT03647124· Celgene· Source

• Completed

  Optimal Detection of Atrial Fibrillation in TIA

  NCT04075500· Alfried Krupp Krankenhaus· Source

• Completed

  EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin)

  NCT03594110· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma

  NCT03761108· Phase 1/2· Regeneron Pharmaceuticals· Source

• Completed

  Coordinated Reset Deep Brain Stimulation

  NCT03732898· Boston Scientific Corporation· Source

• Completed

  Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)

  NCT03713593· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Pomalidomide, Ixazomib, and Dexamethasone With or Without Intensification by Cyclophosphamide in Relapsed or Refractory Multiple Myeloma

  NCT03731832· Phase 2· GWT-TUD GmbH· Source

• Terminated

  Efficacy and Safety of Thrombectomy in Stroke With Extended Lesion and Extended Time Window

  NCT03094715· University Hospital Heidelberg· Source

• Completed

  EGF816 and Trametinib in Patients With Non-small Cell Lung Cancer Harboring Activating EGFR Mutations

  NCT03516214· Phase 1· University of Cologne· Source

• Completed

  A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL

  NCT03467373· Phase 1· Hoffmann-La Roche· Source

• Completed

  Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma

  NCT03361748· Phase 2· Celgene· Source

• Completed

  The Prophet Trial -Pilot Study to Assess Safety and Efficacy of a Novel Atrial Flow Regulator (AFR) in Patients With Pulmonary Hypertension

  NCT03022851· Occlutech International AB· Source

• Completed

  BIOLUMA: Biomarkers for Nivolumab and Ipilimumab and Evaluation of the Combination in Lung Cancer

  NCT03083691· Phase 2· Lung Cancer Group Cologne· Source

• Completed

  A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma

  NCT02908672· Phase 3· Hoffmann-La Roche· Source

• Completed

  Colchicine for Prevention of Vascular Inflammation in Non-cardio Embolic Stroke

  NCT02898610· Phase 3· University College Dublin· Source

• Terminated

  AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia

  NCT02675452· Phase 1· Amgen· Source

• Completed

  A Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-3)

  NCT02614066· Phase 1/2· Kite, A Gilead Company· Source

• Completed

  Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma

  NCT02360579· Phase 2· Iovance Biotherapeutics, Inc.· Source

• Completed

  Cardiac Magnetic Resonance GUIDEd Management of Mild-moderate Left Ventricular Systolic Dysfunction.

  NCT01918215· Flinders University· Source

• Completed

  Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma

  NCT01909453· Phase 3· Pfizer· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Multiple myeloma115 works · 12 trials
• Heart failure96 works · 11 trials
• Parkinson disease58 works · 10 trials
• Amyloidosis26 works · 4 trials
• Fabry disease18 works · 3 trials
• Migraine18 works · 0 trials
• Acute lymphoblastic leukaemia18 works · 2 trials
• Cushing's syndrome16 works · 1 trial
• Hypertrophic cardiomyopathy13 works · 2 trials
• Systemic sclerosis (scleroderma)13 works · 1 trial
• Essential tremor10 works · 3 trials
• Diffuse large B-cell lymphoma10 works · 4 trials
• Cytomegalovirus infection8 works · 2 trials
• Dystonia8 works · 4 trials
• Ankylosing spondylitis8 works · 1 trial
• Mantle cell lymphoma6 works · 3 trials